Gomez Sergio M, Caniza Miguela, Fynn Alicira, Vescina Cecilia, Ruiz Clau-Dia, Iglesias Daniela, Sosa Fernanda, Sung Lillian
Stem Cell Transplantation Unit, Hospital de Niños Sor María Ludovica, La Plata, Argentina.
Global Pediatric Medicine, Infectious Diseases. St. Jude Children's Cancer Research Hospital, Memphis, TN, USA.
Transpl Infect Dis. 2018 Aug;20(4):e12913. doi: 10.1111/tid.12913. Epub 2018 May 14.
Our primary objective was to describe the incidence of proven or probable invasive fungal infections (IFIs), a devastating complication of hematopoietic stem cell transplant (HSCT), in HCST in a middle-income country. Secondary objectives were to describe factors associated with IFIs and outcomes. In this single center retrospective study, pediatric patients who underwent a first allogeneic or autologous HSCT from 1998 to 2016 were included. Of the 251 HSCT recipients: 143 transplants were allogeneic and 108 were autologous. Overall, 23 (9%) experienced an IFI, mostly due to yeasts (83%). IFIs were more common in allogeneic HSCT (18/143, 13%) than in autologous HSCT (5/108, 5%; P = .045). Of the 23 patients with IFIs, 14 (61%) died, but only 1 directly from IFI (pulmonary aspergillosis). Overall survival at 3 years was 0.42 ± 0.11 in patients with IFIs and 0.60 ± 0.37 in those without IFIs (P = .049). In Argentina, IFIs during HSCT are common. Recipients of allogeneic HSCT are at higher risk, and IFI is associated with reduced overall survival. Future work should focus on interventions to reduce and improve IFI outcomes in children undergoing transplants in low- and middle-income countries.
我们的主要目标是描述在一个中等收入国家的造血干细胞移植(HSCT)中,确诊或疑似侵袭性真菌感染(IFI)(造血干细胞移植的一种毁灭性并发症)的发生率。次要目标是描述与IFI相关的因素及预后情况。在这项单中心回顾性研究中,纳入了1998年至2016年接受首次异基因或自体HSCT的儿科患者。在251名HSCT受者中:143例移植为异基因移植,108例为自体移植。总体而言,23例(9%)发生了IFI,主要由酵母菌引起(83%)。IFI在异基因HSCT中(18/143,13%)比在自体HSCT中(5/108,5%;P = 0.045)更常见。在23例发生IFI的患者中,14例(61%)死亡,但只有1例直接死于IFI(肺曲霉病)。发生IFI的患者3年总生存率为0.42±0.11,未发生IFI的患者为0.60±0.37(P = 0.049)。在阿根廷,HSCT期间的IFI很常见。异基因HSCT受者风险更高,且IFI与总生存率降低相关。未来的工作应侧重于采取干预措施,以降低并改善低收入和中等收入国家接受移植儿童的IFI预后。